Biostock interview Chordate CEO Anders Weilandt about the scientific article in Neurology: “absolutely crucial for the company’s overall value”

Biostock has interviewed Chordate’s CEO, Anders Weilandt, about the study results from the company’s PM007 study, which have now been published in the journal Neurology, as well as the significance for the company’s valuation and ongoing exit process.

“It is absolutely crucial for the company’s overall value – and especially in the exit process – that we now have the evidence of Ozilia’s clinical efficacy published. This significantly boosts our marketing and sales efforts in our focus markets and reimbursement discussions. Most importantly, the exit process gains an invaluable addition: a highly compelling argument for why it makes sense to invest in acquiring this asset”, says Anders Weilandt to Biostock.

Read the full interview

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia®, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy